Search Results

Blood Cancer United Named to Inaugural “Best Companies for Working with Cancer” Index

Blood Cancer United® has been named one of the inaugural Best Companies for Working with Cancer, a national recognition from Cancer and Careers, the l…

Equipo ejecutivo y de liderazgo

Conozca a los equipos de liderazgo de Blood Cancer United. Equipo ejecutivo

CAR T-cell Therapy and Transplant: Individualized Treatment Choices and Sequencing for Optimal Outcomes

* required.Breakfast Symposium will be held during the Oncology Nursing Society's (ONS) 51st Annual Congress. Participants must be registered for the …

Communities Across the U.S. Unite in 10‑Week Challenge to Support Blood Cancer Patients

Communities Across the U.S. Unite in ‑Week Challenge to Support Blood Cancer Patients

America’s Most Beautiful Bike Ride Unites Cyclists Against Blood Cancer in Lake Tahoe

America’s Most Beautiful Bike Ride Unites Cyclists Against Blood Cancer in Lake Tahoe

Understanding the drug resistance mechanism and developing new therapeutic strategies for Hairy Cell Leukemia variant

Most of the Hairy Cell Leukemia variant patients do not respond to conventional therapies. They develop resistance to the chemotherapy drugs and we wi…

BRAF and BCL2 coinhibition with vemurafenib and venetoclax as a rational, short, all-oral targeted therapy for relapsed/refractory hairy cell leukemia

We will test the first fully oral, drug combination that simultaneously blocks two different key survival mechanisms in hairy cell leukemia. First, i…

Sophia

Gabriel is years old, and like most kids his age, he loves animals, being outside, and riding his scooter around the neighborhood.But his story looks…

Tracy

I have multiple myeloma (MM), diagnosed in , and had my first stem cell transplant in . I relapsed six months later, then had my second stem cell tra…

Mike

I was diagnosed with acute lymphoblastic leukemia (ALL) at years old in New York. Two and a half years of aggressive chemotherapy later, I was .Six y…

Deb

I run, coach, and fundraise in memory of my dad, Roy.My dad was first diagnosed with chronic lymphocytic leukemia (CLL) in . After rounds of chemo, we…

Mehr

I am a medical student in the United States. Almost four years ago, at years old, I was diagnosed with chronic myeloid leukemia (CML). At that age, …

Olivia

I was diagnosed with classic Hodgkin lymphoma (HL) in at the age of . It changed my whole world; suddenly, my schedule was packed with various appoin…

Quality of Life, Outcomes, and Decision Making for Patients with Hairy Cell Leukemia

We aim to determine if rigorous assessment of quality of life (QOL) can help with treatment decisions for hairy cell leukemia (HCL). We will first ana…

Gregory Abel

I am a hematologic oncologist and cancer care delivery researcher. The focus of my research is to improve quality of life (QOL) and quality of care fo…

Lori

When my husband Ken was first diagnosed and treated for acute myeloid leukemia (AML) it felt like we were trapped in a fierce storm and being tossed a…

Key Insights: Treating Acute Myeloid Leukemia (AML)

IL7 receptor-targeted CAR T-cell Therapy for T-Acute Lymphoblastic Leukemia (T-ALL)

On the basis that acute lymphoblastic leukemia () cells overexpress receptor (IL7R), which promotes chemotherapy resistance and relapse, we develope…

Jae Park

Jae Park, MD is an Attending Physician and Chief of Cellular Therapy Service, and a Director of Adult Acute Lymphoblastic Leukemia Program at Memorial…

CD19-CAR T cells as Consolidation for Older Adults with Acute Lymphoblastic Leukemia in Remission

This proposal examines the use of CD19-directed chimeric antigen receptor (CD19-CAR) T cell immunotherapy to treat adults aged years or older who hav…

Stephen Forman

Stephen J. Forman, MD, is a , international expert in leukemia, lymphoma, and bone marrow transplant (BMT), and pioneer in immunotherapy. Dr. Forman h…

Dear volunteers: You’re the thread that unites us

Volunteers are woven through the fabric of Blood Cancer United. Read a message of gratitude and impact from CEO E. Anders Kolb, MD.

Towards clinical testing of epitope editing to enable novel adoptive immunotherapies

Innovations in gene engineering have made it possible to reprogram immune cells to attack specific targets on cancer cells, allowing the first adoptiv…

Pietro Genovese

In the last years, I developed gene editing tools to improve cancer immunotherapy or promote safer applications of human hematopoietic stem cell (HSC…

Jing Fu

Dr. Jing Fu is an Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons. She earned her PhD in Bio…